Welcome to our dedicated page for Lumexa Imaging Holdings SEC filings (Ticker: LMRI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lumexa Imaging Holdings, Inc. filings document the public-company record for a Nasdaq-listed outpatient medical imaging provider. The company’s disclosures cover its common stock, completed initial public offering, registration statement history, stockholder agreements and capital-structure matters.
LMRI regulatory filings include definitive proxy materials for annual meeting votes and governance matters, Form 8-K reports on financial results, Regulation FD updates, executive transition and compensation arrangements, and material financing agreements. Debt-related filings describe the company’s senior secured credit facility, revolving credit arrangements, maturity terms, interest-rate framework and restrictive covenants affecting operating subsidiaries.
Lumexa Imaging Holdings, Inc. reported insider equity activity for its Chief Legal Officer and Corporate Secretary, Julie Szeker, dated December 12, 2025. A transaction coded “M” involved 1,250,000 incentive units of Lumexa Imaging Equity Holdco, LLC tied to 66,182 shares of common stock, which, according to the footnotes, had been converted into stock at the closing of the company’s initial public offering with replacement awards subject to time- and performance-based vesting conditions.
Following the reported activity, Szeker directly beneficially owned 147,263 shares of common stock, including 11,876 shares that vest only if the stock reaches a volume-weighted average price of $24.97 over a 60-trading-day period after the IPO lock-up expires, subject to continued service. She also holds 81,081 restricted stock units, each representing one share of common stock, scheduled to vest in full on December 12, 2026, provided she continues serving the company.
Lumexa Imaging Holdings, Inc. executive Julie Szeker, the company’s Chief Legal Officer and Corporate Secretary, reported initial beneficial ownership of several equity awards linked to Lumexa common stock. She holds common units in Lumexa Imaging Equity Holdco, LLC that correspond to 12,617 shares of common stock that may be distributed after a 180‑day IPO lock‑up, plus incentive units corresponding to 66,182 shares, including 11,876 shares subject to performance-based vesting.
She also holds three stock option grants to purchase 41,665, 22,222 and 63,887 shares of common stock at an exercise price of $18.5 per share, each expiring in 2035. One option is fully vested, another vests in five annual installments starting February 8, 2023, and about 64.1% of the performance-based grant has vested, with the remainder vesting only if the stock achieves a volume‑weighted average price of $24.97 over 60 consecutive trading days after the IPO lock‑up period, while she continues in service.
Lumexa Imaging Holdings, Inc. disclosed stock option holdings for its Chief Medical Officer, who is an officer of the company. The filing shows two stock options, each giving the right to buy 194,444 shares of common stock at an exercise price of $18.5 per share, both expiring on 12/10/2035.
One option vests annually in five substantially equal installments starting from a vesting commencement date of August 1, 2025, conditioned on continued service. The other option vests in three substantially equal installments if the share price reaches targets of $27.00, $36.00, and $45.00 per share, based on the volume weighted average closing price over any consecutive 60 trading days after a 180-day lock-up period, also requiring continued service. The filing notes it was submitted late due to delays in receiving EDGAR codes.
Lumexa Imaging Holdings, Inc. completed its initial public offering, selling 25,000,000 shares of common stock at a price of $18.50 per share. The company plans to use the net proceeds to repay a portion of its borrowings under a secured term loan facility with Barclays Bank PLC and for working capital, capital expenditures and other general corporate purposes.
In connection with becoming a public company, Lumexa appointed four new directors to staggered board classes, entered into indemnification agreements with all directors and executive officers, and put into effect its amended and restated certificate of incorporation and bylaws, consistent with descriptions in its IPO prospectus.
Lumexa Imaging Holdings, Inc. reports the equity interests of a director and Chief Executive Officer in connection with their role at the company. The executive beneficially owns common units of Lumexa Imaging Equity Holdco, LLC that correspond to 14,948 shares of Lumexa’s common stock, which may be received after the closing of the company’s IPO when Lumexa Imaging Equity Holdco, LLC is permitted to distribute shares following a 180-day lock-up period.
The disclosure also lists two stock option awards, each covering 833,333 shares of common stock at an exercise price of $18.5 per share, expiring on 12/10/2035. One option vests in five substantially equal annual installments beginning on January 1, 2025, while the other vests in three equal tranches upon achieving volume-weighted average price targets of $27.00, $36.00 and $45.00 per share over any consecutive 60-trading-day period after the 180-day IPO lock-up, in each case subject to the executive’s continued service with the issuer.
Lumexa Imaging Holdings, Inc. disclosed that one of its directors holds a stock option covering 422,222 shares of common stock at an exercise price of $18.5 per share. This statement reflects the director’s beneficial ownership as a single reporting person.
According to the filing, 222,222 shares underlying the option have already vested. The remaining shares will vest in three substantially equal installments on November 27 of 2026, 2027 and 2028, and each installment depends on the director continuing to provide service to the company. This structure ties a large portion of the director’s potential equity interest to ongoing tenure with Lumexa Imaging.
Lumexa Imaging Holdings, Inc. reported that one of its directors holds two stock option grants over the company’s common stock. The event date for this insider ownership report is 12/11/2025.
Each stock option (right to buy) relates to 22,222 shares of common stock at an exercise price of $18.5 per share and has an expiration date of 12/10/2035. One grant vests in five substantially equal annual installments from April 26, 2022, and the other vests in five substantially equal annual installments from April 1, 2024, in each case subject to the director’s continued service with the company.
Lumexa Imaging Holdings, Inc. director reports beneficial ownership of a stock option covering 22,222 shares of common stock at an exercise price of $18.5 per share, expiring on 12/10/2035.
The option vests in five substantially equal annual installments starting from a vesting commencement date of March 1, 2025, and each installment requires the director to continue serving with the company. The option is held directly.
Lumexa Imaging Holdings, Inc. filed an initial statement of beneficial ownership for Welsh, Carson, Anderson & Stowe–affiliated entities that are identified as both directors and 10% owners. These reporting persons disclose indirect holdings of Lumexa Imaging common stock through Common Units of Lumexa Imaging Equity Holdco, LLC (Holdings LLC), where each nine Common Units represent the right to acquire one share of common stock held by Holdings LLC.
The filing lists multiple blocks of common stock underlying these derivative securities, including 17,646,994 shares attributable to Welsh, Carson, Anderson & Stowe XII, L.P., 3,219,023 shares for Welsh, Carson, Anderson & Stowe XII Cayman, L.P., and 3,267,506 shares for WCAS Co-Invest Holdco, L.P. After Lumexa Imaging’s initial public offering and a 180-day lock-up period, Holdings LLC may distribute its common stock pro rata to remaining equity holders, at which time these indirect interests may be settled into Lumexa Imaging shares in connection with such a distribution.